Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and sildenafil

moxifloxacin has been researched along with sildenafil in 14 studies

Compound Research Comparison

Studies
(moxifloxacin)		Trials
(moxifloxacin)		Recent Studies (post-2010)
(moxifloxacin)		Studies
(sildenafil)		Trials
(sildenafil)		Recent Studies (post-2010) (sildenafil)
3,1575521,690134060

Protein Interaction Comparison

ProteinTaxonomymoxifloxacin (IC50)sildenafil (IC50)
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)20
Chain A, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain B, cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)20
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)20
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)20
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0024
Chain A, cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.0024
Phosphodiesterase Bos taurus (cattle)9.2
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)2.881
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit deltaHomo sapiens (human)0.0187
cGMP-specific 3',5'-cyclic phosphodiesteraseRattus norvegicus (Norway rat)0.0012
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)2.881
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.2626
High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9AHomo sapiens (human)4.2
cGMP-specific 3',5'-cyclic phosphodiesteraseCanis lupus familiaris (dog)0.0024
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaBos taurus (cattle)0.0374
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus8.247
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 28.247
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alphaBos taurus (cattle)0.0545
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A Bos taurus (cattle)0.78
cAMP-specific 3',5'-cyclic phosphodiesterase 4D Rattus norvegicus (Norway rat)4.6
cAMP-specific 3',5'-cyclic phosphodiesterase 4CRattus norvegicus (Norway rat)4.6
cAMP-specific 3',5'-cyclic phosphodiesterase 4BRattus norvegicus (Norway rat)4.6
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit alphaHomo sapiens (human)0.0187
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Bos taurus (cattle)0.0366
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaHomo sapiens (human)0.0187
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaBos taurus (cattle)0.0374
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit betaBos taurus (cattle)0.0374
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)7.9333
Adenosine receptor A2aHomo sapiens (human)0.253
Adenosine receptor A1Homo sapiens (human)1.493
Delta-type opioid receptorRattus norvegicus (Norway rat)0.04
Prostaglandin G/H synthase 2Homo sapiens (human)0.003
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit betaHomo sapiens (human)0.0187
Cone cGMP-specific 3',5'-cyclic phosphodiesterase subunit alpha'Homo sapiens (human)0.0418
cAMP-specific 3',5'-cyclic phosphodiesterase 4ARattus norvegicus (Norway rat)4.6
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)0.7199
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaCanis lupus familiaris (dog)0.0182
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BBos taurus (cattle)0.78
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)1.8841
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BRattus norvegicus (Norway rat)0.3
Synaptic vesicular amine transporterRattus norvegicus (Norway rat)0.01
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)6.3336
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)8.52
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)5.7005
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)3.3075
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)4.7337
High affinity cAMP-specific 3',5'-cyclic phosphodiesterase 7AHomo sapiens (human)4.69
Retinal cone rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit gammaHomo sapiens (human)0.0187
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)0.7398
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)4.6677
cGMP-specific 3',5'-cyclic phosphodiesteraseBos taurus (cattle)0.557
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CRattus norvegicus (Norway rat)0.3
Indoleamine 2,3-dioxygenase 2Mus musculus (house mouse)4.5
Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit deltaBos taurus (cattle)0.0374
Phosphodiesterase Rattus norvegicus (Norway rat)0.3
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11AHomo sapiens (human)4.1584
cAMP-specific 3',5'-cyclic phosphodiesterase 7BHomo sapiens (human)3.6006
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10AHomo sapiens (human)4.2432

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (57.14)29.6817
2010's5 (35.71)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M1
Keserü, GM1
Nagashima, R; Nishikawa, T; Tobita, M1
Andricopulo, AD; Moda, TL; Montanari, CA1
Lombardo, F; Obach, RS; Waters, NJ1
Jia, L; Sun, H1
Caron, G; Ermondi, G; Visentin, S1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV1
Sen, S; Sinha, N1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW1

Reviews

1 review(s) available for moxifloxacin and sildenafil

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

13 other study(ies) available for moxifloxacin and sildenafil

ArticleYear
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
    Journal of medicinal chemistry, 2002, Aug-29, Volume: 45, Issue:18

    Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship

2002
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
    Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16

    Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship

2003
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
    Bioorganic & medicinal chemistry letters, 2005, Jun-02, Volume: 15, Issue:11

    Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated

2005
Hologram QSAR model for the prediction of human oral bioavailability.
    Bioorganic & medicinal chemistry, 2007, Dec-15, Volume: 15, Issue:24

    Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Support vector machines classification of hERG liabilities based on atom types.
    Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11

    Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve

2008
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
    European journal of medicinal chemistry, 2009, Volume: 44, Issue:5

    Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship

2009
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
    Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

    Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations

2010
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:2

    Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship

2011
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
    Journal of medicinal chemistry, 2021, 12-09, Volume: 64, Issue:23

    Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors

2021